Develops alpha-emitting radiopharmaceutical (radioligand) therapies that deliver targeted radiation directly to tumors.
Develops alpha-emitting radiopharmaceutical (radioligand) therapies that deliver targeted radiation directly to tumors.
Has no product on sale and earns nothing from customers, so development is funded by money raised from investors and potentially partners. Its value rests on clinical results for one family of cancer drugs.
Moat: narrow (IP / patents, process know-how). Radiopharmaceutical manufacturing and isotope supply-chain know-how are hard for new entrants to build.
Headquarters: Boston, Massachusetts, US · Founded: 2019 · Employees: 79
Size Aktis Oncology (AKTS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $895M, the 2298th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.10 on 18 Nov 2026.
Performance Over six months the shares fell 15.4%, against -24.5% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 19 in its peer set.
Growth Revenue grew 336.9% over the last twelve months (peer median +9.2%); the operating margin is -837.5% (peer median 7.1%).
Valuation It trades at 33.4× enterprise value to sales against a peer median of 3.8× (2nd most expensive of 17).
Short interest Short interest is 8.2% of the free float (30 Oct 2026).
Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | $12.4M | $6.50M | $1.49M | $0 |
| Revenue growth | — | +337% | — | — |
| Gross profit | $9.22M | $4.17M | -$88,000 | -$1.12M |
| EBITDA | -$101M | -$72.4M | -$50.5M | -$33.7M |
| Net income | -$87.5M | -$63.7M | -$44.0M | -$28.6M |
| Free cash flow | n/a | -$73.7M | $11.9M | -$33.8M |
| Capital expenditure | n/a | $9.58M | $2.86M | $3.76M |
| Total debt | $10.8M | $11.5M | $12.0M | $13.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Aktis Oncology AKTS | $895M | -15% | +337% | -837% | 33.4× | n/a |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 5.0× | 14.4% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AKTS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.1% | -9.3% | 5th highest of 21 |
| 6-month return | -15.4% | -24.5% | 8th highest of 19 |
| Distance from 52-week high | -52.9% | -44.1% | 5th lowest of 21 |
| Revenue growth (TTM) | +336.9% | +9.2% | 3rd highest of 18 |
| Operating margin | -837.5% | 7.1% | lowest of 18 |
| EV / Sales | 33.4× | 3.8× | 2nd most expensive of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | 33.4× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | 0.9× | -7.6% | -0.7% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | 55.9× | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | 8.5× | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 2.6× | -3.7% | +13.8% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 5.2× | 9.1% | +13.4% |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 7.5× | -10.2% | +18.1% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 8.3× | 17.7% | +22.7% |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 2.2× | 2.4% | +12.4% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | 0.8× | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 4.1× | 31.7% | +4.2% |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | 6.5× | n/a | n/a |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 0.9× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | 4.5× | 10.3% | -13.7% |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 1.2× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 1.2× | -4.2% | +10.6% |